Volver al buscador
FDAFDA · Alimentos y medicamentos·N.º oficial Z-0039-2013

IDS Urine BETA CrossLaps ELISA, Catalog Number AC-05F1. Type of packaging: Cardboard Box containing plastic bottles. The Urine BETA CrossLaps® ELISA is an enzyme immunological test for the quantification of degradation products of C-terminal telopeptides of Type-I collagen in human urine. The Urine BETA CrossLaps® ELISA assay is intended for in vitro diagnostic use as an indication of human bone resorption as an aid in A. Monitoring bone resorption changes of 1) Anti-resorptive therapies in postmenopausal women: a) Hormone Replacement Therapies (HRT) with hormones and hormone like drugs b) Bisphosphonate therapies B. Predicting skeletal response (Bone Mineral Density) in postmenopausal women undergoing anti-resorptive therapies a) Hormone Replacement Therapies (HRT) with hormones and hormone like drugs b) Bisphosphonate therapies

Publicado el 17 de octubre de 2012 · Inicio del retiro: 10 de agosto de 2012

Resumen

FDA registra el retiro Z-0039-2013 de dispositivos médicos de Clase II, publicado el 17 de octubre de 2012 e iniciado el 10 de agosto de 2012. Empresa responsable: Immunodiagnostics Systems Ltd; Estado: Finalizado; Cantidad reportada: 1; Lote: Lot 14541, EXP Nov 2012. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.

Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.

Qué peligro representa

It has been noted by staff at IDS Inc. that stock of the affected products held at IDS Inc. are labeled with IVD labels although they are not registered for sale as IVDs in the United States. The products should have been labeled as Research Use Only or Investigational use only dependent on their usage.

Qué hacer

Voluntary: Firm initiated · E-Mail

Recibe un correo cuando FDA publique un retiro como este

Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.

Detalles del retiro

Fabricante
Immunodiagnostics Systems Ltd
Distribuidor
Nationwide Distribution including NY, CA, ME and CT.
Lote
Lot 14541, EXP Nov 2012
Clasificación de riesgo
Class II
Área (FDA)
device
País
United Kingdom

Retiros relacionados

Preguntas sobre este retiro

¿IDS Urine BETA CrossLaps ELISA, Catalog Number AC-05F1. Type of packaging: Cardboard Box containing plastic bottles. The Urine BETA CrossLaps® ELISA is an enzyme immunological test for the quantification of degradation products of C-terminal telopeptides of Type-I collagen in human urine. The Urine BETA CrossLaps® ELISA assay is intended for in vitro diagnostic use as an indication of human bone resorption as an aid in A. Monitoring bone resorption changes of 1) Anti-resorptive therapies in postmenopausal women: a) Hormone Replacement Therapies (HRT) with hormones and hormone like drugs b) Bisphosphonate therapies B. Predicting skeletal response (Bone Mineral Density) in postmenopausal women undergoing anti-resorptive therapies a) Hormone Replacement Therapies (HRT) with hormones and hormone like drugs b) Bisphosphonate therapies fue retirado del mercado?

Sí. FDA publicó el retiro Z-0039-2013 el 17 de octubre de 2012. Peligro reportado: It has been noted by staff at IDS Inc. that stock of the affected products held at IDS Inc. are labeled with IVD labels although they are not registered for sale as IVDs in the United States. The products should have been labeled as Research Use Only or Investigational use only dependent on their usage.

¿Qué debo hacer si tengo este producto?

Voluntary: Firm initiated · E-Mail